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Abstract
Objective—Myofascial trigger points (MTrPs) are focal disruptions in skeletal muscle that can 
refer pain to the head and reproduce the pain patterns of tension-type headache (TTH). The present 
study applied massage focused on MTrPs of subjects with TTH in a placebo-controlled, clinical 
trial to assess efficacy on reducing headache pain.
Methods—Fifty-six subjects with TTH were randomized to receive 12 massage or placebo 
(detuned ultrasound) sessions over six weeks, or to wait-list. Trigger point release (TPR) massage 
focused on MTrPs in cervical musculature. Headache pain (frequency, intensity and duration) was 
recorded in a daily headache diary. Additional outcome measures included self-report of perceived 
clinical change in headache pain and pressure-pain threshold (PPT) at MTrPs in the upper 
trapezius and sub-occipital muscles.
Results—From diary recordings, group differences across time were detected in headache 
frequency (p=0.026), but not for intensity or duration. Post hoc analysis indicated headache 
frequency decreased from baseline for both massage (p<0.0003) and placebo (p=0.013), but no 
difference was detected between massage and placebo. Subject report of perceived clinical change 
was a greater reduction in headache pain for massage than placebo or wait-list groups (p=0.002). 
PPT improved in all muscles tested for massage only (all p's<0.002).
Discussion—Two findings from this study are apparent: 1) MTrPs are important components in 
the treatment of TTH, and 2) TTH, like other chronic conditions, is responsive to placebo. Clinical 
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trials on headache that do not include a placebo group are at risk for overestimating the specific 
contribution from the active intervention.
Keywords
Episodic tension-type headache; chronic tension-type headache; complementary medicine; 
headache frequency; algometer
Introduction
Tension-type headache (TTH) is a widespread and major health concern. The one-year 
prevalence of episodic and chronic tension-type headache is 38% and 2-3%, respectively [1, 
2]. Tension-type headache affects daily functioning, resulting in limitations in performance 
and participation [1]. Although TTH is the most prevalent headache disorder, resulting in 
greater societal burden than migraine, investigation into interventional avenues lags other 
headache categories such as migraine. [3-5] Others have stressed the need for development 
of treatment interventions for TTH with fewer side effects than currently recommended 
medications [6].
In recent years the myofascial trigger point (MTrP) has become a site of interest in the 
pathology of TTH. Patients with TTH exhibit increased presence and tenderness of MTrPs 
in pericranial muscles. There is evidence to suggest that the presence and pain sensitivity of 
MTrPs are sufficient to make distinctions between headache and non-headache populations 
[7-9]. MTrPs within skeletal muscle are characterized by a number of physical features 
including a palpable tender nodule within a taut muscular band, point tenderness at the 
nodule, characteristic patterns of referred pain and the presence of a local twitch response 
when stimulated [10]. To underscore the importance of the MTrP and its relationship to 
headache, one prominent and recurring theory is that progression from episodic to chronic 
forms of TTH is related to prolonged nociceptive input from peripheral myofascial tissues, 
which sensitize the central nervous system, thereby increasing its excitability. [11, 12] While 
pathogenesis of TTH remains unclear and is likely multifactorial, MTrPs have an intriguing 
connection to TTH in that active MTrPs can elicit referred pain phenomenon that reproduce 
patient pain complaints, thus providing a direct connection between peripheral tissue and the 
central pain of headache. [7, 12-18] In recent years, interventions directed at a MTrP have 
led to reduction in local pain, referred pain intensity, and the extent of referred pain fields 
originating from the MTrP in both headache and non-headache populations. [19, 20]
Treatment that addresses MTrPs has been emphasized as an interventional strategy for 
management of TTH. [21] To that end, several pilot studies with a focus on the MTrP have 
found positive effects in primary clinical measures of TTH. [22, 23] Preliminary research 
also indicates that interventions that address the MTrP as part of a more comprehensive 
treatment plan may be beneficial in the management of TTH [24-26]. Two recent non-
controlled studies were designed to identify clinical characteristics of TTH patients likely to 
achieve short-term success with myofascial trigger point therapy. [27, 28] In the earlier 
study, four variables were identified for immediate short-term (headache duration < 8.5 
hour/day, headache frequency < 5.5 days/week, bodily pain < 47, vitality < 47.5) and two 
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variables stood out at the 1-month follow-up (headache frequency < 5.5 days/week and 
bodily pain < 47). The second study identified eight prognostic factors from the history and 
physical examination of TTH patients that link to treatment success of myofascial trigger 
point therapy for TTH. The eight variables were punctuated by six that are associated with 
myofascial trigger points or cervical musculature: the presence of MTrP's in the 
suboccipitals, left sternocleidomastoid, left superior oblique; referred pain area of right 
upper trapezius MTrP, total muscle tenderness score, and reduced cervical rotation to the 
left. Age less than 44.5 years and a score of 18.5 or less on the Neck Disability Index test 
constitute the remaining two prognostic factors. The authors report that patients expressing 5 
or more variables exhibit an increased likelihood of treatment success with myofascial 
trigger point therapy. While techniques that reduce MTrP pain are a logical interventional 
target for TTH, no randomized, placebo-controlled trial has been conducted to determine the 
efficacy of an intervention focused solely on the MTrP for reducing headache pain. [29]
While many techniques exist that can impact MTrPs, massage therapy is particularly 
interesting due to its availability [30], relatively low cost [31], patient interest [32], 
informality, and treatment effectiveness. [19, 33] The aim of the present study was to 
determine the efficacy of trigger point release (TPR) massage for reducing tension-type 
headache pain in a randomized, placebo-controlled trial. Secondary aims were to determine 
the effects of multiple TPR massage sessions on MTrP tenderness and assess quality of life 
variables in those with TTH.
Methods
The present study conformed to International Headache Society (IHS) guidelines for the 
design of randomized clinical trials for headache. [34] Study procedures were approved by 
the Colorado Multiple Institutional Review Board (COMIRB) at the University of Colorado 
Denver. Informed consent was obtained from all subjects prior to study enrollment. The trial 
is registered at ClinicalTrials.gov, number NCT01244555.
Study population
Subjects were recruited from a large metropolitan setting near a University hospital. All 
subjects were screened for TTH by an anesthesiologist (JK) with specialty experience in 
headache. Participants were recruited and enrolled between September 2010 and May 2012.
For inclusion in the study, participants had to have two or more headaches per week meeting 
International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria for TTH 
defined as head pain of bilateral location, pressing or tightening quality, mild to moderate 
intensity, and not aggravated by routine physical activity (e.g. walking or stair climbing). 
[35] Both of the following criteria also had to be met: no nausea or vomiting in association 
with the headache; and no more than one of the following two symptoms, photophobia or 
phonophobia. Participants between the ages of 18-59 years of age were recruited. Exclusion 
criteria included migraine (>1/month), headache originating from a secondary cause (e.g. 
cancer or injury), fibromyalgia, diabetes, major depression, neurological or cardiovascular 
disease, pregnancy, use of professional massage or ultrasound specifically for headache in 
the prior 6 months. Subjects taking prophylactic medication for headache were also 
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excluded; abortive medication was permitted provided a self-reported use for no more than 
75 % of headache episodes. All subjects were screened by a massage therapist for the 
presence of at least one active MTrP in the primary (bilateral) muscles addressed (upper 
trapezius, suboccipital muscles, sternocleidomastoid).
Design
The study was a randomized, placebo-controlled clinical trial conducted in three consecutive 
phases: baseline (4 weeks), treatment (6 weeks), and run-out (4 weeks). The treatment phase 
was divided into two three-week phases in order to detect any treatment plateau (Figure 1). 
Headache was recorded in a daily headache diary for the duration (14 weeks) of the study. 
Immediately prior to the first treatment session, subjects were block randomized (blocks of 
six) to receive massage, placebo, or wait-listed. Individuals randomized to massage or 
placebo were then scheduled for twice weekly sessions over six weeks for a maximum of 12 
treatment sessions. Subjects randomized to the wait-list group did not attend intervening 
sessions.
All subjects were informed, prior to consenting, that they could receive the alternate 
treatment (massage or ultrasound) program upon completion of the study free of charge. 
During the run-out phase, subjects received no intervention. No subject reported initiating a 
new treatment intervention during the 14 week study. All interventions and assessments 
were conducted at the Clinical and Translational Research Center (CTRC) at the University 
of Colorado Hospital.
Interventions
Each massage or placebo session was 45 minutes in duration, administered twice per week, 
and separated by at least 48 hours.
Massage—All of the massage therapists who delivered that intervention had state licensure 
in Colorado to practice massage, prior training and work experience in the identification of 
MTrPs, at least 3 years of professional practice experience, and regular use of the general 
massage techniques used in the protocol. Massage therapists underwent two 3-hour study 
protocol training sessions to ensure consistent application of the massage procedure. Each 
massage therapist was observed by the lead massage therapist (NB) on three unannounced 
occasions to confirm adherence to massage protocol administration. Only minimal 
deviations from protocol were observed and none detected after the first observation session. 
Six massage therapists participated in the study. Subjects were assigned a primary therapist 
for the study duration based on therapist and subject schedules. No therapist was assigned to 
more than five subjects.
Each massage session followed a standardized protocol lasting 45 minutes, consisting of 15 
minutes of myofascial release to warm soft tissues of the back, shoulders, chest, and neck 
[36]; 20 minutes of trigger point release (TPR) applied bilaterally to address MTrPs in the 
upper trapezius, the sub-occipital muscle groups, and the sternocleidomastoids [22, 37]; the 
final 10 minutes consisted of post-isometric relaxation directed at right and left lateral 
cervical flexion, circular or cross-fiber friction on the masseter, temporalis, and occipital-
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frontalis muscles, as well as gentle effleurage and petrissage to the neck and shoulders [38, 
39]. The upper trapezius, sub-occipital muscles, and the sternocleidomastoids were selected 
for TPR treatment due to the high frequency of MTrPs in these muscles that refer pain to the 
head and reproduce the subject headache pain complaint. [16, 21, 40]
MTrPs were identified using published criteria. [10] Briefly, muscles were palpated for a 
tender nodule along taut bands within the respective muscle groups. Force was progressively 
applied to the nodule with the patient instructed to verbally indicate whether they felt pain 
locally or in other areas (referred pain). For sites where the subject indicated referred pain, 
subjects were asked whether the pain was familiar (e.g. reproduced their typical headache). 
If multiple MTrPs were identified within a muscle, the MTrP that reproduced the subjects' 
typical headache (active MTrP) was addressed. If no active MTrP was identified the most 
tender site was treated. TPR was applied as follows: pincer grip of sufficient force to just 
elicit referred pain (or 6 on a 10-point scale) was applied to the identified site. Duration was 
until subject verbally reported dissipation of referred pain, the therapist detected a physical 
softening in the MTrP, or a maximum of 60 seconds had elapsed. Up to five compressions 
were performed at each site with a 10-second rest between compressions to allow blood 
reperfusion. TPR has been extensively used by our research team [22, 41] and others.[42-44]
Placebo—Proper placebo control for massage-based studies is inherently difficult since 
many sham treatments lack plausibility for the health issue or could inadvertently contribute 
a therapeutic benefit. A proper control intervention for massage must seem plausible for the 
ailment, account for contextual aspects of the intervention such as patient-therapist 
individual time, and incorporate a tactile interaction with the subject. Detuned ultrasound 
(US) meets all of these parameters as it: 1) is believable as an intervention for MTrPs [33, 
45-48]; 2) controls for therapist-subject interaction; 3) involves tactile contact with the 
subject; and 4) provides no potentially effective treatment. Furthermore, patients are unable 
to distinguish an active from an inactive US treatment, thus ensuring that blinding was 
maintained. [49, 50]
Detuned US was administered by a nurse or nurse's aide who had received a one-hour 
training on ultrasound application from a certified ultrasound technician. Nurses were used 
due to the high plausibility for a nurse to administer this type of intervention in a medical 
setting, thus enhancing the believability of the placebo intervention. Detuned-US was 
administered using a Dynatron 150plus (Dynatronics Corporation, 7030 Park Centre Drive, 
Salt Lack City, UT 84121) with display settings at 1W/cm2 intensity, 1.0Mhz frequency, 
and 20% duty cycle. A non-functional soundhead (5cm2) provided by the manufacturer was 
used. A standardized protocol was followed to ensure consistency in its application. Subjects 
were seated in a massage chair with detuned-US administered sequentially to four regions of 
the upper back and neck to approximate location of the left and right upper trapezius and 
sub-occipital muscle groups. Water soluble coupling agent (ScripHessco Ultrasound Gel, 
Script ScripHessco 360 Veterans Parkway, Suite 115, Bolingbrook, IL 60440-4607) was 
applied to the skin surface and the soundhead moved in small overlapping circles at a rate of 
2-3cm/s. Each region was treated for 10 minutes with the area cleaned of coupling agent 
before proceeding to the next region. Each US session lasted 45 minutes.
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Eight nurses or nurse's aides participated in the study; each was observed by the certified 
ultrasound technician on one unannounced visit to assess US application and confirm 
treatment protocol compliance. No technical deviations were observed. Both nurses and 
subjects were blind to the non-functional nature of the ultrasound equipment.
Wait-list group—A wait-list comparator group was included to assess the natural course 
of TTH over time. Subjects randomized to this group did not receive any intervention, but 
completed all assessments in a time-matched manner. They maintained and returned their 
headache diaries similar to the massage and placebo groups.
All subjects and study personnel were blind to subject group assignment until immediately 
prior to the first treatment intervention (Figure 1) when a sealed envelope was opened that 
designated group assignment. Envelopes containing group allocation were prepared by 
departmental staff not affiliated with the study, but with guidance from the study statistician.
Outcome measures
Daily Headache Diary—Subjects maintained a paper daily headache diary for the 
duration of the study (14 weeks) with each phase representing three (treatment phase A and 
B) or four (baseline and run-out) week intervals. Diary recordings of three to four weeks 
have been shown to be reliable for headache measures in research investigations. [34, 51] 
Subjects recorded headache frequency, duration (hours and minutes), use of pain medication 
for headache, and headache pain intensity (100 mm visual analog scale (VAS) with anchors 
of “No headache pain” and “Maximum headache pain”). Diaries were returned by mail or 
directly to study personnel at two week intervals. Headache frequency was calculated as a 
weekly average for each subject during the time frame measured; headache duration and 
intensity are presented as the average value recorded per headache during the time frame 
measured; non-prescription medication use for headache was calculated as a weekly sum of 
the number of doses taken.
Perceived clinical change—Participant perceived change in headache pain was 
recorded on a 15 point scale ranging from -7 to +7. [56] Descriptors were provided with the 
numerical range where 0 was associated with “about the same;” ±1, “A tiny bit better/
worse;” ± 2, “A little bit worse/better;” ± 3, “Somewhat worse/better;” ± 4, “Moderately 
worse/better;” ± 5, “Quite a bit worse/better;” ± 6, “A great deal worse/better;” ± 7, “A very 
great deal worse/better.” Subjects recorded perceived change in headache pain just prior to 
the final treatment (end of the treatment phase) and at the end of the four week run-out 
relative to how they felt at the start of treatment.
Pressure-Pain Threshold (PPT)—PPT was assessed bilaterally in the upper trapezius 
and subobccipital muscles using pressure algometry (Wagner FPN 50 algometer, Wagner 
Instruments, Inc. Greenwich, CT). Briefly, muscles were palpated for MTrPs as described 
above. [10] When multiple MTrPs were identified, measurement was conducted at the site 
that generated referral pain reproducing the subjects' typical headache (e.g. active MTrP). If 
no active MTrP was identified, assessment was made at the most tender site identified. The 
algometer tip was placed over the site and force slowly applied until the subject verbally 
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indicated that sensation changed from pressure to pain. The average of three assessments at 
the same site is reported; no change in PPT was detected across replicate measures (all 
p's>0.23 for each muscle group). A 20 second recovery was given between measurements. 
PPT was conducted immediately before randomization into treatment group and the final 
(12th) treatment visit, or, in the case of the wait-list group at a time- matched period six 
weeks after the first assessment. In all cases, the final PPT assessment was conducted at 
least 48 hours following any previous intervention session. Measurement of PPT in the SCM 
was not conducted due to the sensitive location and lack of a smooth, hard surface (e.g. 
bone) from which to apply constant pressure. Due to technical reasons it was not possible to 
blind the assessor to subject treatment group assignment.
Quality of life—The impact of headache on daily life was assessed by two validated 
questionnaires that capture different aspects of headache-associated disability. 
Questionnaires were administered at three time points: 1) the end of baseline phase 
(immediately prior to randomization); 2) the end of the treatment phase (six weeks later); 3) 
and at the end of run-out. Assessment at the end of treatment occurred just prior to the final 
treatment and at least 48 hours following any previous intervention.
1. The Headache Disability Inventory (HDI) is a principal measure of disability 
focusing on emotional and functional components of headache [52]. The HDI 
consists of 25 questions based on items derived empirically from case history 
responses of participants with headache. Responses are scored requiring a “yes,”2 
points; “sometimes,” 1 point; or “no,” 0 points response. A total score is computed 
by summing all scores resulting in an individual HDI score ranging from 0 (no 
disability) to 100 (severe disability). A decrease in the total HDI score of ≥16 
points is considered to be a clinically significant improvement. [53] The HDI has 
good internal consistency (0.89), robust short- and long-term retest reliability 
(0.83), and good construct validity [52, 53].
2. The Headache Impact Test (HIT-6) is a validated measure for assessing quality of 
life in patients with headache as a function of headache frequency.[34, 54] The 
HIT-6 consists of six items (pain, social functioning, role functioning, vitality, 
cognitive functioning, psychological distress) where respondents select one of five 
options: “never,” 6 points; “rarely,” 8 points; “sometimes,” 10 points; “very often,” 
11 points; “always,” 13 points. Total score ranges from 36 to 78 points. A decrease 
of 2.3 to 8 points among patients with chronic daily headache reflects improvement 
in headache that is considered clinically significant. [55, 56] The HIT-6 has good 
internal consistency (Cronbach alpha 0.89), and sound test-retest reliability (0.80)
[57].
Sample Size Calculation
An a priori power analysis was conducted assuming beta = 0.20, alpha = 0.05, and using 
effect size estimates from data obtained from published research for the primary headache 
indicator (headache frequency) in a preliminary study of massage intervention for tension-
type headache. [22] Based on an effect size (Cohen's d) of approximately 0.84 for headache 
frequency enrollment of 20 subjects per group was anticipated to provide at least 80% power 
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for headache frequency and allow for at least a modest amount of attrition (15%) during the 
study.
Statistical Analysis
All analyses were performed in SAS Version 9.2. All outcomes, with the exception of 
perceived clinical change, were modeled in a multilevel modeling framework in SAS Proc 
Mixed as linear mixed models. The models included a treatment main effect to determine an 
overall difference between groups and a time main effect to determine whether scores 
changed over time. The primary interest was in the treatment by time interaction to address 
the primary hypothesis that changes over time differed by group. If a significant treatment 
by time interaction was observed (e.g. p<0.05), simple effects tests were conducted to 
examine how scores changed over time within each of the three groups. The same modeling 
framework was followed for all outcomes, although there were four timepoints for headache 
diary outcomes (baseline, first half of treatment (phase A), second half of treatment (phase 
B), and end of run-out), two timepoints for PPT outcomes (baseline and end of treatment), 
and three timepoints for the HDI and HIT-6 (baseline, end of treatment, end of run-out). 
Several potential confounding variables were identified: age, gender, race/ethnicity, 
headache diagnosis (chronic or episodic), years with TTH, recent history of professional 
massage, activity level, depression, and anxiety. Each potential covariate was tested to 
determine whether it differed by condition or was related to the primary headache outcomes. 
None of these tests were statistically significant. Consistent with prior literature, the 
perceived clinical change score was broken down into four categories: 0 = No change, ±1 to 
±3 = Small change; ±4 to ±5 = Moderate change; and ±6 to ±7 = Large change.[58] Fisher's 
exact test was used to test for differences in the proportion of those reporting no, small, 
moderate, or large change across the three conditions. ANOVA models were used to assess 
mean change in headache frequency from baseline to the end of treatment and run-out across 
the four change categories (collapsed across condition).
Results
A total of 184 individuals were assessed for study eligibility; 69 met eligibility and were 
enrolled (Figure 2). Five subjects were removed from the study prior to randomization due 
to incorrect headache diagnosis based on headache diary recordings; two subjects withdrew, 
prior to randomization, due to conflict with scheduling. Sixty-two subjects were randomized 
to massage (20), placebo (21) or wait-list (21) groups. Six subjects (3 in massage, 2 in 
placebo, 1 in wait-list) subsequently withdrew or were lost to follow-up. To examine 
whether the data from those who completed the study could generalize to those who 
dropped, the completer group was compared to the dropped group on baseline demographic 
and headache variables. Of 25 tests conducted, the only significant difference between 
groups was on headache duration, where duration was significantly higher in the group who 
dropped due to a single outlier. Overall, this provides evidence that those who dropped were, 
on average, similar to those retained.
Table 1 depicts demographic information for the 56 subjects analyzed in the study, by 
treatment group. The three groups did not differ statistically in terms of any of the 
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demographic variables examined. On average, subjects were 33.5 years old and the majority 
were female, Caucasian, employed full time, and had experienced TTH for an average of 8.9 
years (SD = 6.9). Participants attended a mean of 11.6 (SD, 1.0) massage and 11.5 (SD, 
0.84) placebo sessions of the planned 12 sessions (p=0.96).
Table 2 depicts the results of the analyses examining treatment effects on changes in 
headache outcomes over time. Means ± standard error are presented for each timepoint, by 
treatment group. Treatment group differences were detected in changes in headache 
frequency over time (F (6, 52) = 2.65, p=0.026). Post-hoc analysis identified that headache 
frequency decreased for both massage (p=0.0003) and placebo (p=0.013) relative to their 
baseline but not for the wait-list group (p=0.098). No statistical difference was detected 
between the massage and placebo treatment groups (p=0.26). The pattern of means for 
headache frequency are also illustrated in Figure 3, and, as shown, the largest difference 
between conditions was during the second phase (phase B) of treatment (p=0.033). No 
significant treatment group differences were detected for headache duration, headache 
intensity, or medication use.
Table 3 shows group effects on quality of life measures across time. Significant condition 
effects were observed on changes in HDI (F(4,52) = 3.26, p = 0.019) and HIT-6 (F(4,52) = 
3.27, p = 0.018). Post-hoc tests showed a significant decrease in HDI scores in the 
intervention group (p = 0.0003) but not in the placebo (p = 0.06) or wait-list (p = 0.39) 
groups; a significant change in HIT-6 scores was detected over time in both the intervention 
(p = 0.0002) and placebo (p = 0.011) groups but not in the wait-list group (p = 0.52).
Perceived clinical change in headache pain is presented in Table 4. In the first set of 
analyses, the proportion of subjects reporting changes in headache pain across the three 
conditions was assessed. The results of the Fisher's exact test comparing reported change 
across the three conditions was significant both at the end of treatment and at the end of run-
out. At post-treatment, the vast majority of those in the massage condition reported moderate 
or large improvement (84.7%), compared with 50% in the placebo group and 0% in the 
wait-list group (p<0.001). In contrast, 82.4% of those in the wait-list condition reported no 
change. These patterns were maintained at the end of run-out where 64.3% of those in the 
massage group reported moderate or large improvement compared to 36.8% in the placebo 
condition and 6.25% in the wait-list control condition (p=0.002).
Table 4 also shows the mean change in headache pain that corresponds to change category 
membership. There were significant differences in the change in headache pain across the 
four categories at both assessment timepoints. A reduction of approximately 2 headaches 
(1.88-2.11) per week corresponded to a subject reported “large” perceived change.
Changes in MTrP PPT from start to end of the six week treatment phase are shown in Table 
5. There was a significant time by treatment interaction for all four sites tested (F values 
ranged from 4.49 to 7.91, p values ranged from <0.001 to 0.015). Post hoc analyses showed 
that scores significantly improved in the massage group (p values ranged from <0.001 to 
0.002 across outcomes), but did not change in the placebo and waitlist groups (all p's > 
0.17).
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The present clinical trial found that six-week programs of massage therapy, with an 
emphasis on MTrPs in key cervical musculature, or placebo (detuned ultrasound) were both 
efficacious for reducing headache frequency in a mixed population of episodic or chronic 
TTH. No statistical difference between massage and placebo was found for headache 
frequency as recorded on headache diary, although self-report of perceived clinical change 
detected greater improvement for those who received massage at both immediately post-
intervention and end of run-out timepoints. Group or time changes to secondary headache 
measures (intensity and duration) were not impacted by massage or placebo, nor was 
medication use changed as measured by number of weekly doses consumed for headache 
pain.
Statistical change for secondary non-headache, quality of life measures was noted in both 
the HDI and HIT-6 questionnaires, with post-hoc statistical separation between massage and 
placebo groups detected for the HDI, but not the HIT-6. Only the change from baseline in 
the HIT-6 achieved the threshold to be considered clinically significant. [55] Finally, 
assessment of pressure-pain threshold (PPT) at MTrPs of the upper trapezius and sub-
occipital muscles increased for subjects who received massage, but did not change for 
placebo or wait-list groups. This measure was conducted at least 48 hours after any 
treatment indicating a sustained effect in PPT for those who received massage.
The treatment phase of the present study was divided into two halves (phases A & B) to help 
identify a possible treatment plateau. For the massage intervention, a small reduction in 
headache frequency was detected from baseline to the first half (0.34 HA/week) of 
intervention; greater reduction in headache frequency (1.01 HA/week) was noted during the 
second half of the treatment phase. Aggravation of MTrPs can lead to increased local pain. 
[59] With direct pressure from TPR-massage at MTrPs coupled with uncertainty of optimal 
treatment pressure, it is possible that multiple sessions are needed to effect meaningful 
change or that gains from early sessions are counter-balanced by losses from aggravation of 
MTrPs. The effect of placebo intervention on headache frequency was the reverse, i.e. 
greater reduction in headache frequency occurred during the first three weeks (0.6 HA/
week) with an additional gain of about half that during the second half of the treatment 
phase (0.29 HA/week). It is not clear if additional massage or placebo sessions beyond the 
12 would provide additional benefit although 75% of those receiving massage and 53% in 
the placebo group reported a belief that additional sessions would be beneficial.
The origin of pain in TTH remains unknown, although both peripheral and central factors 
likely play a role in its pathophysiology. Episodic (ETTH) and chronic (CTTH) tension-type 
headache populations report increased presence of MTrPs in pericranial musculature [7, 13, 
15, 40] that, when stimulated, precisely reproduce the typical headache complaint. It was 
hypothesized that massage of MTrPs in the cervical musculature would result in a reduction 
in headache pain. Our study provides some evidence that increase in MTrP PPT is a 
mechanism underlying the positive effect of intervention on headache frequency. 
Supplementary mediational analysis showed that massage intervention predicted change in 
MTrP PPT from beginning to end of the treatment phase (p < .001) and that the change in 
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PPT predicted a decrease in the average number of headaches from the baseline to the 
follow-up period (p < 0.001). These analyses show that MTrP PPT change may be one 
mechanism by which reduction in headache occurs. However, since headache frequency also 
decreased in the placebo condition, even though the placebo treatment did not impact trigger 
point tenderness, a separate mechanism for headache reduction is likely. Since the placebo 
treatment contained all aspects of the massage treatment except an active intervention, it is 
probable that some of the observed gains in the massage group are related to contextual 
factors of the intervention.
A qualitatively altered pain perception and generalized hyperalgesia lead current thought 
that headache pain in CTTH is the result of chronic central sensitization, suggesting 
differing pain generation mechanisms between episodic and chronic TTH while questioning 
the role of MTrPs once CTTH has been established. [11, 60] Active MTrPs in TTH patients 
could be a source of frequent noxious stimuli to the CNS that assists in transforming ETTH 
to CTTH. Our study, suggests that a reduction in pericranial myofascial nociception (e.g. 
increased PPT) remains an important component for reducing headache frequency in both 
frequent episodic or chronic TTH.
Identification of individuals with TTH likely to respond to MTrP-based therapies is 
important for treatment efficacy. In our study, individuals presented with at least one active 
MTrP, but also had multiple other criteria described by Fernandez-de-la Penas as relevant to 
TTH for responsiveness to MTrP therapy. [27, 28] Subjects in the present study met the 
criteria for age, headache frequency and duration, as well as presence of MTrPs in cervical 
muscles, which are proposed characteristics correlated with greater likelihood for successful 
outcome from MTrP therapy. Our findings, in a clinical trial setting, give support to the 
clinical prediction rule for identification of subjects responsive to MTrP therapies.
The massage protocol used in the study was highly structured, with muscles most commonly 
associated with pain referral to the head (upper trapezius, sub-occipitals, and 
sternocleidomastoid) addressed for MTrPs during each visit. While this consistency 
enhanced reproducibility of procedure, it may have limited treatment efficacy as pericranial 
muscles (e.g. temporalis, superior oblique, masseter, levator scapula) also generate referred 
pain from MTrPs and may contribute to TTH [40, 61]. In the present study, some subjects 
had few active MTrPs in the muscles addressed, which could have resulted in limited 
improvement if MTrPs in other muscles were active in contributing to headache. Freedom 
for the therapist to palpate for, and address, MTrPs in a subject's most problematic muscles, 
in a pragmatic study design, would be helpful in identifying the treatment potential of TPR-
massage for TTH.
Several limitations in our study should be noted. The study was powered to identify whether 
a TPR-focused massage could reduce headache pain relative to a wait-list population rather 
than compared to placebo intervention. While no statistical difference was observed from 
diary recordings between TPR-massage and placebo for headache frequency, self-report did 
indicate a difference in overall headache pain. Further research is needed to establish if a 
difference between placebo and TPR-massage exists. We screened for subjects presenting 
with TTH and excluded those with >1 migraine per month. The selection criteria resulted in 
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a population largely free of non-TTH headache, which suggests the results are not 
generalizable to individuals with other headache types. Furthermore, while individuals with 
either frequent episodic and chronic TTH were recruited, the individuals who responded and 
met enrollment criteria were predominantly CTTH or experienced ETTH with 8 or more 
headaches per month; suggesting that the study findings are most relevant to those with 
greater headache frequency.
To our knowledge, this study marks for the first time, a placebo effect for a TTH 
interventional study. Inclusion of a placebo intervention for headache studies has been 
limited, especially for studies of TTH. [62] It is an important consideration because 
investigations involving placebo interventions can have profound implications [63]. 
Blinding of both subjects and those who administer a physical intervention is extremely 
difficult, but of critical importance. Interventional studies for TTH involving medications 
have found placebo medications may be as effective as an active medication, highlighting 
the need for placebo-controlled trials in body-oriented therapies, as well [64]. For studies 
involving physical therapies, placebo in the form of medication fails to address potentially 
important contextual aspects of an intervention such as patient-therapist individual time as 
well physical interactions. Furthermore, a placebo treatment that focuses on a non-affected 
area (e.g. foot massage) would likely raise doubts among subjects regarding its potential 
value and possibly leading to subject drop-out. Blinding of the technician who administers 
treatment is also important to study integrity since subjects may be influenced by 
practitioner behavior [65]. We addressed this last concern by keeping social interaction 
between subject and practitioner to a minimum and keeping the ultrasound technicians blind 
to the non-functional nature of the device.
In recent years, MTrPs have received increased attention for their role in TTH. While 
massage that focused on MTrPs and placebo both reduce tension headache frequency, their 
respective mechanisms of action for headache reduction may be different. Our findings 
suggest that reduction in MTrP PPT may be an important treatment avenue for addressing 
TTH pain although contextual factors associated with intervention also contribute to 
improvement in headache frequency.
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Study timeline for the 14 week clinical trial depicting the four week baseline, two 3-week 
treatment phases, the four week run-out, and time points for outcome measure assessments. 
Key: HA – headache; PPT – pressure-pain threshold; QoL – quality of life; PCC- perceived 
clinical change.
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Subject flow diagram illustrating subjects assessed for eligibility, randomization to groups 
(massage, placebo, and wait-list), and number analyzed in the study.
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Headache frequency means ± standard error over the four study phases (baseline, first and 
second halves of treatment, run-out) for the three study groups (massage, placebo, and wait-
list). Values represent the average number of headache days per week during the respective 
time frame. Significant change from baseline was detected for massage (p=0.0003) and 
placebo (p=0.013), but not for wait-list (p=0.098).
Moraska et al. Page 19











































Moraska et al. Page 20
Table 1
Subject demographic and headache information by treatment group
Demographic Variable
Massage (N=17) Placebo (N=19) Wait-list (N=20)
Mean ±SD or % Mean ±SD or % Mean ±SD or %
Age 32.1 ± 12.0 34.7 ± 11.1 33.4 ± 9.0
% Female 88.2% 89.5% 80.0%
% White 88.2% 79.0% 85.0%
% Committed relationship / Married 35.3% 36.8% 40.0%
% Employed Full Time 64.7% 68.4% 80.0%
Headache
 Chronic TTH 64.7% 52.6% 45.0%
 Episodic TTH 35.3% 47.4% 55.0%
Years with TTH 8.18 ± 6.6 9.34 ± 6.9 9.05 ± 7.5
Treatment Sessions Attended 11.6 ± 1.0 11.5 ± 0.84 -
Note. All comparisons between groups were non-significant (all ps > 0.44). TTH, Tension-type Headache
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